Turku, Finland, October 10, 2017: Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels as demonstrated in preclinical models. This selective activity is expected to allow safer long-term treatment of this chronic disease without harmful symptoms of estrogen deficiency.
Southampton, UK, 3 October 2017 – Vantia Therapeutics announces positive top-line data from a pivotal Phase III trial investigating the efficacy and safety of fedovapagon (VA106483) in the treatment of nocturia in men with benign prostatic hyperplasia (BPH) (the "EQUINOC" study). The EQUINOC trial is a 432-patient randomised, double-blind, placebo-controlled, multi-centre study conducted in the US. Patients were randomised to receive fedovapagon or placebo orally each evening over a 12-week treatment period.
At an Extraordinary General Meeting on Friday, Jean-Luc Butel, Senior Advisor at McKinsey & Company Healthcare Systems & Services, and Fran-cis Cuss, former Executive Vice President and Chief Scientific Officer of Bristol-Myers Squibb, were elected as new members of the Board of Direc-tors of Novo Holdings A/S.
Sten Scheibye, Chairman of the Board of Directors of Novo Holdings, says: "I am delighted that Jean-Luc Butel and Francis Cuss are joining the Board of Novo Holdings. They both bring profound business experience and comprehensive insights from their impressive international careers in the life-science sector. This will strengthen and further develop Novo Holdings as we aim to increase our investments in the life sciences."
Novo Holdings is the holding and investment company of the Novo Group with total assets of DKK 275.7 billion (USD 43.6 billion) as of the end of 2016. Novo Holdings is wholly owned by the Novo Nordisk Foundation and currently wholly or partly owns more than 80 life-science companies, many of which are headquartered in the United States. Last year, the company invested DKK 8.7 billion (USD 1.37 billion) in life-science companies. The strategy of Novo Holdings is to substantially increase its investments in life-science companies over the coming years.
Stepping up the strategic development of two gene-therapy drug candidates
Strengthening the medical and operational management team
Paris, France and Cambridge, MA, US – September 19, 2017 - Lysogene (FR0013233475 – LYS), a leading clinical-stage biopharmaceutical company specializing in gene therapy technology applied to central nervous system diseases, is today reporting its results for the first half of 2017, as approved by the Board of Directors on September 15, 2017, and providing an update on activities.
Karen Aiach, Lysogene’s CEO, made the following comments: “The successful IPO in February has helped accelerating progress in terms of both our clinical operations and our management team. We achieved a number of important strategic milestones during the first half of 2017, including setting-up a unique international observational natural history study in Sanfilippo syndrome A (MPS IIIA), and signing a manufacturing agreement with a first-class contract manufacturing organization based in the US to produce our gene therapy candidate for GM1 gangliosidosis (GM1). This faster development has been supported by the expertise and enthusiasm of our team, which has been strengthened by the arrivals of Mr Philippe Mendels-Flandre, Chief Operating Officer, and Dr Sophie Olivier, Chief Medical Officer. Lysogene will continue this trajectory in the second half of 2017, as we execute the preparation for the phase II/III trial in MPS IIIA”.
Antag Therapeutics ApS is founded on decades of seminal research focused on peptide-based drugs and dietary-related metabolic diseases from Professors Mette M. Rosenkilde and Jens J. Holst at the University of Copenhagen. In collaboration with clinicians from Gentofte and Bispebjerg hospital, the team has discovered a naturally occurring peptide-antagonist of the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor and has conducted several human studies with demonstrated effects on fat metabolism.
Novo A/S, the holding company for the companies in the Novo Group, is changing its name to Novo Holdings A/S.
The new name will more accurately reflect the company’s role and will help to re-duce any confusion with the other companies in the Novo Group.
In connection with the new name, Novo Holdings will add the tagline "Investors in life science". This clarifies that the company is a life-science focused investor, in addition to being the holding company of the Novo Group.
Novo Holdings currently wholly or partly owns more than 80 life-science compa-nies, many of which are headquartered in the United States. Last year, the com-pany invested DKK 8.7 billion in the life sciences. The strategy of Novo Holdings is to substantially increase its investments in life-science companies over the coming years.
Danish-based Dermtreat today announced the launch of its phase 1b study of the Rivelin® patch – a breakthrough therapy in treating mucosal diseases.
Dermtreat has developed the Rivelin® patch – a breakthrough therapy for the treatment of mucosal diseases. Rivelin® is designed to deliver a pharmaceutical drug uni-directional to a mucosal surface – using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface.
Company expands sales force throughout the U.S. to meet increasing customer demand
ALISO VIEJO, Calif. – May 31, 2017 – Cianna Medical, Inc., today announced that it is doubling its sales force and adding to its clinical application support team to meet the growing demand for its proprietary SCOUT® radar localization system. The additional personnel will continue to drive rapid adoption of SCOUT as the standard of care for pre-operative breast lesion localization and enable the company to leverage significant growth opportunities in key markets across the country.
SCOUT® is the market leader in non-radioactive, wire-free breast localization systems. With SCOUT, the radiologist places a tiny, highly sophisticated reflector at the tumor site with extreme precision. The technology, which has been rapidly adopted at leading medical facilities across the U.S., offers several benefits over other localization methods including operating room (OR) compatibility, ± 1mm detection accuracy and no significant MR compatibility artifact limitations.
Zurich, Switzerland, May 31, 2017 – Inthera Bioscience, a Swiss biopharmaceutical company developing first-in-class targeted small molecule therapies for solid tumors, today announced the closing of a Series A financing of CHF 10.5 million (EUR 9.6 million).
The financing round was led by Merck Ventures, with equal contribution from Aglaia BioMedical Ventures and Novo Seeds and the participation of a private investor. In conjunction with the financing round, Emmanuelle Coutanceau of Novo Seeds and Keno Gutierrez of Merck Ventures have joined the company’s Board of Directors. Earlier this year, the Board of Directors had already been strengthened with two experienced biotech executives, Klaus Schollmeier, who has assumed the Chairman role, and Anker Lundemose, joining as independent member.
Genoa Pharmaceuticals, Inc., a biopharmaceutical company focused on development of improved therapies for idiopathic pulmonary fibrosis (IPF) and other severe pulmonary indications, today announced the completion of a $62 million Series A financing. The round was led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners, with participation by Novo AS, RiverVest Venture Partners, and TPG Biotech.
Read the full press release here.
Orphazyme ApS, a Danish biotech company developing novel therapies for the treatment of
protein misfolding diseases, today announced the completion of enrolment for its lead program
within Niemann-Pick type C disease.
Read full press release here.
Dermtreat raises USD 17.7 million from from Sofinnova Ventures, Novo A/S and Lundbeckfonden.
Copenhagen, Denmark – May 8, 2017: Danish-based Dermtreat today announced the successful closure of a USD 17.7 mill. Series A financing led by the US-based leading venture capital firm, Sofinnova, with the leading Nordic venture capital firms Novo Seeds and Lundbeckfonden Emerge in the syndicate. Existing shareholders are also participating.
Munich / Hellerup, 12 April 2017 – SYNLAB Limited (“SYNLAB” or “the Group”), a European market leader for laboratory diagnostics, and Novo A/S (“Novo”), the holding company for the Novo Group and fully owned subsidiary of the Novo Nordisk Foundation, today jointly announce that Novo has agreed to increase its equity stake in the Group through a €250m subscription to new shares. Following the closing of the transaction which is scheduled to take place today, Novo will own a stake of approximately 20% of the equity of SYNLAB.
Read the full press release here.
For 16 years, Lars Rebien Sørensen was President and CEO of Novo Nordisk A/S, a leading global pharmaceutical company with a focus on diabetes care. With Lars Rebien Sørensen at the helm, the company’s annual results increased markedly, and in 2016 the company produced its best results ever. Harvard Business Review ranked Lars Rebien Sørensen as the world’s top-performing CEO in 2015 and 2016.
Read the full press release here.
Novo A/S announces the proposed acquisition of a 19.95% shareholding in ConvaTec Group Plc, a UK listed global medical products and technologies company with leading market positions in advanced wound care, ostomy care, continence and critical care and infusion devices. At completion of the transaction, Kasim Kutay, CEO of Novo A/S, will join the Board of Directors of ConvaTec Group Plc.
Click here to read the press release.
Sonion today announced the appointment of Jesper Ahlmann Funding Andersen as the President & CEO of the Sonion Group. Jesper replaces Jørn Mørkeberg Nielsen who was President & CEO of Sonion until the end of 2016.
Click here to read Sonion's news release.
Novo A/S, holdingselskabet i Novo Gruppen, øgede sine nye investeringer i life-science- virksomheder fra 3,2 mia. kr. i 2015 til 8,7 mia. kr. i 2016. Novo A/S foretog investeringerne som del af en strategi, der har til formål at styrke selskabets position som en internationalt førende life-science-investor.
Klik her for at læse pressemeddelelsen.
Novo A/S, the holding company of the Novo Group, increased its new investments in life science companies from DKK 3.2 billion in 2015 to DKK 8.7 billion in 2016 as part of a strategy to strengthen the position of Novo A/S as a leading international life science investor.
Click here to read the press release.
Click here to see the video with Kasim Kutay's introduction of Novo A/S.
Copenhagen March 9, 2017
Orphazyme ApS today announced the successful completion of a EUR 14M financing round. Two new investors, LSP and the ALS Investment Fund joins the investor syndicate comprising Kurma Partners, Idinvest Partners, Novo A/S, Sunstone Capital and Aescap Venture.
Click here to read Orphazyme's news release.